Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nisha Pillay

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Progress in Biophysics and Molecular Biology|February 1, 2021
DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapyNisha Pillay, Rosie M Brady, Malini Dey, et al.
Breast (Edinburgh, Scotland)|February 20, 2026
Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient surveyEva Schumacher-Wulf, Lesley Fallowfield, Runcie C W Chidebe, et al.
Nature|November 23, 2022
Structural basis of tankyrase activation by polymerizationNisha Pillay, Laura Mariotti, Mariola Zaleska, et al.
Breast (Edinburgh, Scotland)|November 26, 2025
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9)Alexandru Eniu, Runcie C W Chidebe, Peter Vuylsteke, et al.
NAR Cancer|July 17, 2024
Intrinsic PARG inhibitor sensitivity is mimicked by <i>TIMELESS</i> haploinsufficiency and rescued by nucleoside supplementationCamilla Coulson-Gilmer, Samantha Littler, Bethany M Barnes, et al.
Cancer Cell|March 20, 2019
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase InhibitorsNisha Pillay, Anthony Tighe, Louisa Nelson, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Progress in Biophysics and Molecular Biology|February 1, 2021
DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapyNisha Pillay, Rosie M Brady, Malini Dey, et al.
Breast (Edinburgh, Scotland)|February 20, 2026
Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient surveyEva Schumacher-Wulf, Lesley Fallowfield, Runcie C W Chidebe, et al.
Nature|November 23, 2022
Structural basis of tankyrase activation by polymerizationNisha Pillay, Laura Mariotti, Mariola Zaleska, et al.
Breast (Edinburgh, Scotland)|November 26, 2025
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9)Alexandru Eniu, Runcie C W Chidebe, Peter Vuylsteke, et al.
NAR Cancer|July 17, 2024
Intrinsic PARG inhibitor sensitivity is mimicked by <i>TIMELESS</i> haploinsufficiency and rescued by nucleoside supplementationCamilla Coulson-Gilmer, Samantha Littler, Bethany M Barnes, et al.
Cancer Cell|March 20, 2019
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase InhibitorsNisha Pillay, Anthony Tighe, Louisa Nelson, et al.
Pageof 1